Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?
Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?
复制标题
DOI：
10.1097/coc.0000000000000123
复制
发表时间：
2015-08
期刊：
影响因子：
--
通讯作者：
Oklu R
中科院分区：
文献类型：
--
作者：
Hesketh RL;Zhu AX;Oklu R
“组学革命”通过改进肝细胞癌（HCC）的诊断、分期、治疗和监测，促进了一种个性化的方法来改善结果。此外，能够在分子水平上靶向一系列特定肿瘤驱动因素的前景，为这种众所周知难以治疗的疾病提供了令人兴奋的新治疗前景。我们将我们对HCC发展的分子机制的理解与循环肿瘤细胞和放射基因组学的潜力结合起来，提供了一个独特的视角，以改变当前实践中使用的决策驱动因素。
The ’omics revolution is facilitating a personalized approach to improving outcome by refining diagnosis, staging, treatment and monitoring of hepatocellular carcinoma (HCC). Furthermore, the promise of being able to target a range of specific tumor drivers at a molecular level offers exciting new therapy prospects for a disease that is notoriously difficult to treat. We provide a unique perspective combining our understanding of the molecular mechanisms of HCC development with the potential of circulating tumor cells and radiogenomics to change the drivers of decision-making used in current practice.